Ubs Group Ag Scynexis Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Scynexis Inc stock. As of the latest transaction made, Ubs Group Ag holds 15,008 shares of SCYX stock, worth $17,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,008

Previous 15,003 0.03%

Holding current value

$17,709

Previous $30,000 26.67%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.27 - $2.23 $6 - $11	5 Added 0.03%	15,008 $22,000
Q2 2024 Aug 13, 2024	BUY	$1.4 - $2.77 $21,000 - $41,550	15,000 Added 500000.0%	15,003 $30,000
Q4 2023 Feb 09, 2024	SELL	$1.56 - $2.24 $5,079 - $7,293	-3,256 Reduced 99.91%	3 $0
Q3 2023 Nov 09, 2023	BUY	$1.93 - $3.64 $6,289 - $11,862	3,259 New	3,259 $7,000
Q1 2023 May 12, 2023	SELL	$1.15 - $3.0 $3,451 - $9,003	-3,001 Reduced 59.44%	2,048 $6,000
Q4 2022 Feb 08, 2023	SELL	$1.46 - $2.94 $912 - $1,837	-625 Reduced 11.02%	5,049 $7,000
Q3 2022 Nov 10, 2022	BUY	$1.83 - $2.93 $5,032 - $8,057	2,750 Added 94.05%	5,674 $14,000
Q2 2022 Aug 10, 2022	BUY	$1.77 - $3.87 $5,175 - $11,315	2,924 New	2,924 $5,000
Q1 2022 May 16, 2022	SELL	$3.56 - $6.66 $8,814 - $16,490	-2,476 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.94 - $7.69 $12,063 - $18,778	2,442 Added 7182.35%	2,476 $15,000
Q3 2021 Nov 15, 2021	SELL	$5.3 - $7.89 $4,271 - $6,359	-806 Reduced 95.95%	34 $0
Q2 2021 Aug 13, 2021	SELL	$6.5 - $9.97 $505,648 - $775,586	-77,792 Reduced 98.93%	840 $6,000
Q1 2021 May 12, 2021	BUY	$6.93 - $9.63 $83,755 - $116,388	12,086 Added 18.16%	78,632 $624,000
Q4 2020 Feb 11, 2021	BUY	$4.28 - $7.87 $270,299 - $497,021	63,154 Added 1861.85%	66,546 $509,000
Q3 2020 Nov 12, 2020	BUY	$4.37 - $7.48 $14,823 - $25,372	3,392 New	3,392 $15,000

Others Institutions Holding SCYX

# of Institutions

Shares Held

13.7M

Call Options Held

21.9K

Put Options Held

2.6K

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $38.5M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account